ANDAINTRAVENOUSSOLUTION
Approved
Jun 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NEOSTIGMINE METHYLSULFATE (neostigmine methylsulfate) by Sagent Pharmaceuticals is inhibitor. First approved in 2018.
Drug data last refreshed 18h ago
Mechanism of Action
inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on NEOSTIGMINE METHYLSULFATE at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.